CJC-1295 + Ipamorelin

Overview

The CJC-1295 + Ipamorelin co-lyophilised vial is the workhorse GH-axis preparation in 503A compounding workflows, and the most-cited dual-pathway formulation in the published clinical-pharmacology literature. The mechanism rests on two parallel signalling inputs that converge on the same somatotroph cell population. CJC-1295 (no DAC, the Modified GRF 1-29 form) acts at the GHRH receptor, mimicking the hypothalamic GHRH input. Ipamorelin acts at the GHSR (ghrelin receptor), mimicking the alternative ghrelin-driven secretagogue input. Because the two downstream cascades reinforce rather than compete inside the somatotroph, the combination produces GH-release magnitudes well in excess of either component dosed alone at matched amounts, the synergy is the entire rationale for the blend. Vialdyne releases the blend as a co-lyophilised vial against a ≥99.0% main-peak HPLC specification per component. The catalogue ratio is 1:1 by mass (5 + 5 mg per 10 mg total vial); alternate ratios (2+5, 5+10, 10+10) and larger total fills are scoped under a project-specific change-control. The co-lyophilised path is preferred over having the receiving pharmacy reconstitute and combine two separate vials, both peptides are short-half-life, the in-solution ratio drifts during preparation, and the co-lyophilised cake locks the ratio at the freeze-drying step. The released-batch COA certifies both component purities individually and the in-vial ratio rather than just the nominal ratio.

Who buys this, and why

Custom-blend buyers are almost always OEM clients building a branded product around a specific ratio of two or more peptides. The development workflow is collaborative: ratio target, analytical method to verify it, stability protocol in the chosen carrier, and packaging selection are all defined in the OEM brief before the first commercial run. Sample-stage volumes are usually 5-10 g of finished blend; commercial MOQ depends on the components.

Primary buyer fit: 503A / 503B compounding pharmacies and medical aesthetic clinics and med spas.

Specifications

CAS

(blend)

Purity (HPLC)

≥ 99.0% per component

Common vial sizes

10 mg

MOQ

On request

Lead time

10–18 days

Storage

-20°C, protect from light

Documentation available on request

• Certificate of Analysis (COA)
• Ratio-verification HPLC
• Mass-spec identity of each component
• Stability of the blend (matrix-specific)
• Bacterial endotoxin (LAL, USP <85>)
• Sterile-fill documentation (where applicable)
• SDS / MSDS
• Private-label / OEM specification sheet

Regulatory note

Sold as a multi-peptide active for research and for OEM-formulated finished products under the receiving brand's regulatory framework. Blend composition, finished-product safety, labeling claims, and notification responsibilities remain with the brand owner. Component-level analytical data is supplied for every batch.

Frequently asked questions